Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
Andrea Necchi, Daniele Raggi, Patrizia Giannatempo, Laura Marandino, Elena Farè, Andrea Gallina, Maurizio Colecchia, Roberta Lucianò, Andrea Salonia, Giorgio Gandaglia, Nicola Fossati, Marco Bandini, Filippo Pederzoli, Ryan Dittamore, Yang Liu, Elai Davicioni, Jeffrey S. Ross, Joep J. de Jong, Alberto Briganti, Francesco Montorsi, Ewan A. Gibb
Topics & Concepts
Fibroblast growth factor receptor 3Bladder cancerMedicineFibroblast growth factor receptor 4Cancer researchOncologyPathologicalFibroblast growth factor receptor 2Fibroblast growth factor receptorCancerInternal medicineBiologyReceptorFibroblast growth factorBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer-related molecular mechanisms research